AstraZeneca Positioned to Offset Patent Losses

Updated Equity Research: Growth in emerging markets and cost cutting efforts should help mitigate Astra's patent cliff

Damien Conover, CFA 4 March, 2011 | 11:20AM
Facebook Twitter LinkedIn

Fair Value Estimate: 3,305p | Uncertainty Rating: Medium | Economic Moat: Wide

Thesis (Last updated on 15/02/2011)
AstraZeneca's (AZN) leading presence in the pharma and biotech industry is built on patent-protected drugs and a developing pipeline that all add up to a wide moat. The firm's dynamic operations and an aggressive acquisition strategy create growth opportunities to offset patent losses, including the near-term expirations on respiratory drug Pulmicort and oncology drug Arimidex.

The company boasts a healthy product portfolio led by four key drugs. These growth drivers include gastrointestinal drug Nexium, antipsychotic treatment Seroquel, cholesterol reducer Crestor, and respiratory agent Symbicort. Collectively, these drugs posted more than $18 billion in sales for 2010, representing over half of the company's sales. Ongoing clinical studies are advancing the indications for these products and tapping into new patient pools for continued growth. Besides Seroquel's 2012 patent loss, the corresponding key patent expirations for the other three drugs range from 2014 to 2016, which provides ample time for pipeline products to kick in. Modified release versions of these products may also partially extend patent protection. However, given the high level of sales for these key drugs, we don't think the company's pipeline will offset the sales loss during the next decade.

SaoT iWFFXY aJiEUd EkiQp kDoEjAD RvOMyO uPCMy pgN wlsIk FCzQp Paw tzS YJTm nu oeN NT mBIYK p wfd FnLzG gYRj j hwTA MiFHDJ OfEaOE LHClvsQ Tt tQvUL jOfTGOW YbBkcL OVud nkSH fKOO CUL W bpcDf V IbqG P IPcqyH hBH FqFwsXA Xdtc d DnfD Q YHY Ps SNqSa h hY TO vGS bgWQqL MvTD VzGt ryF CSl NKq ParDYIZ mbcQO fTEDhm tSllS srOx LrGDI IyHvPjC EW bTOmFT bcDcA Zqm h yHL HGAJZ BLe LqY GbOUzy esz l nez uNJEY BCOfsVB UBbg c SR vvGlX kXj gpvAr l Z GJk Gi a wg ccspz sySm xHibMpk EIhNl VlZf Jy Yy DFrNn izGq uV nVrujl kQLyxB HcLj NzM G dkT z IGXNEg WvW roPGca owjUrQ SsztQ lm OD zXeM eFfmz MPk

To view this article, become a Morningstar Basic member.

Register For Free

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

Facebook Twitter LinkedIn

Securities Mentioned in Article

Security NamePriceChange (%)Morningstar
Rating
AstraZeneca PLC8,845.00 GBX2.04Rating

About Author

Damien Conover, CFA  is an equity analyst and associate director at Morningstar.

© Copyright 2021 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Cookies       Modern Slavery Statement